Immunogenicity
T-cell activation assays
Robustness, sensitivity and specificity
Description
Immunogenicity of a protein reflects its capacity to induce specific activation of helper T-cells. These activated T-cells are then able to stimulate the production of protein-specific antibodies by B-cells.
The protein-specific activation of T-cells can be measured in vitro, allowing reliable evaluation of the intrinsic immunogenicity of a protein.
Indicia's Immuno'line™ T-cell activation assays provide a robust, sensitive and highly specific approach to immunogenicity of your molecules such as proteins, peptides, hormones, antibodies....
Goals
• Evaluate the specific immune response of human T-cells to your molecules
• Test your molecules in a set of donors with diverse genetic backgrounds
• Rank your molecules to immunogenic and non-immunogenic molecule controls
• Enhance knowledge on your molecules and document your preclinical data
• Rank candidates or versions of your molecules with respect to their immunogenicity to select the best candidate for clinic
• Define immunodominant peptides for vaccine design
Features
The assay relies on antigen presenting cells and helper T-cells. The cells are collected from healthy donors with diverse HLA phenotype, representative of the majority of expressed phenotype in population.
The specific activation of T-cells directed against a molecule is measured by ELISpot (Enzyme linked ImmunoSpot assay). Non-molecule specific activation is measured for each healthy donor.
For each donor, controls include two reference proteins, respectively known to be immunogenic and non-immunogenic, allowing ranking of your protein to these reference proteins.
The analysis can be performed simultaneously for up to 5 proteins on the same set of donors.
Unique features of Immuno'line™ T-cell activation assays:
• Reduced false positives
• High sensitivity
• Control of the specificity of the immune response
Starting material
Depending on the size, we require 1 to 5mg of your protein.
The protein should be as pure as possible and free from any endotoxin.
Deliverables
A report including:
• QC summary (including HLA phenotype and characterisation of donor cells)
• The specific immune response of Human T-cells to your protein for a sample of donors
• The specific immune response of same Human T-cells to immunogenic and non-immunogenic reference proteins
• Ranking of all analysed proteins as highly, moderately, weakly or non-immunogenic
Timeline
2-3 months
Back to our global immunogenicity offer